Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8234157 | 0.84 | SIGMAR1 (0.75) | SIGMAR1KCNH2 | |
| Oxalic Acid SCHEMBL466854 | 0.81 | SIGMAR1 (0.71) | SIGMAR1KCNH2 | |
| SCHEMBL4500443 | 0.78 | SIGMAR1 (1.00) | SIGMAR1KCNH2 | |
| SCHEMBL23005526 | 0.78 | SIGMAR1 (0.51) | SIGMAR1KCNH2 | |
| Oxalic Acid SCHEMBL4515225 | 0.76 | SIGMAR1 (0.94) | SIGMAR1KCNH2 | |
| SCHEMBL9974264 | 0.75 | SIGMAR1 (0.77) | SIGMAR1KCNH2 | |
| SCHEMBL731151 | 0.74 | SIGMAR1 (0.67) | SIGMAR1KCNH2 | |
| SCHEMBL12187054 | 0.72 | SIGMAR1 (0.76) | SIGMAR1KCNH2 | |
| SCHEMBL467006 | 0.72 | SIGMAR1 (1.00) | SIGMAR1KCNH2 | |
| SCHEMBL16424445 | 0.71 | SIGMAR1 (0.54) | SIGMAR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2503994-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING SIGMA RECEPTOR LIGANDS | ESTEVE LABOR DR (ES) | 2017-07-05 | — | — | EP | claimed |
| EP-2503994-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING SIGMA RECEPTOR LIGANDS | ESTEVE LABOR DR (ES) | 2017-07-05 | — | — | EP | disclosed |
| US-9241927-B2 | Pharmaceutical compositions comprising sigma receptor ligands | Laboratories Del Dr, Esteve, S.A. (ES) | 2016-01-26 | — | — | US | disclosed |
| US-20120283262-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING SIGMA RECEPTOR LIGANDS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-11-08 | — | — | US | disclosed |
| EP-2335688-A1 | Pharmaceutical compositions comprising sigma receptor ligands | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2011-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283262-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING SIGMA RECEPTOR LIGANDS | SIGMAR1, OPRM1, OPRL1 | SIGMAR1 1/4885KCNH2 2227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.